Background. Given the limited data, systemic treatment of male breast cancer has been extrapolated from female patients. The 21-gene recurrence score (RS) assay estimates the risk of distant recurrence and chemotherapy benefit in early-stage, ER?/HER2-female breast cancer. We assessed the association between RS and type of treatment in male breast cancer. Methods. We identified male patients with ER?/HER2-breast cancer and available RS results treated at our institution in 2006-2016. We collected data on clinicopathologic features, treatment, and outcome. The Institutional Review Board approved the study. Results. The study cohort consists of 38 male breast cancer patients with a median age of 70 years. Median tumor size was 1.6 cm, and 81.6% (31) were node-negative. RS was low (B 17) in 26 (68.4%) cases, intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) in 9 (23.7%) cases, and high (C 31) in 3 (7.9%) cases, comparable to that in female patients at our institution. All patients underwent total mastectomy, and one received radiotherapy. Thirty-four (89.5%) patients received adjuvant endocrine therapy, mostly tamoxifen (81.6%; 31). Five (13.2%) patients with intermediate or high RS were treated with adjuvant chemotherapy. No locoregional recurrence was observed, and one patient developed distant recurrence (median follow-up 34 months). Conclusions. The RS distribution in male breast cancers was similar to that in females treated at our institution.
Male breast cancer is uncommon, accounting for \ 1% of all cancers in men and \ 1% of all breast cancers. The incidence of male breast cancer has been rising, with an estimated annual incidence of 2470 cases and an annual mortality of approximately 460 cases in the United States. 1 Risk factors include genetics (BRCA mutations, Klinefelter's syndrome), lifestyle (obesity, alcohol consumption, exogenous estrogen), race (African-American ancestry), environment (high ambient temperature, exhaust emissions), testicular and liver damage, and radiotherapy to chest. 2, 3 Up to 40% of male breast cancer is hereditary, in contrast to only 5-10% of female breast cancer.
2,3 BRCA2 germline mutations are more common than BRCA1 mutations. 4 Male breast cancer is usually diagnosed at an advanced stage, 2 most likely related to lack of awareness, screening and prevention. Most tumors are hormone receptor-positive invasive ductal carcinomas, not otherwise specified (IDC NOS). 2, 3 Treatment of male breast cancer is similar to that of female breast cancer, although mastectomy has been the preferred surgical procedure. Few studies have reported important clinical and genomic differences between males and females. [5] [6] [7] Comparison of stage-and subtype-matched patients showed that male breast cancer has a significantly worse overall survival (OS) than female breast cancer. 5, 6 Male breast cancer less frequently harbors somatic genetic alterations typically found in ER-positive, HER2-negative female breast cancer, such as PIK3CA and TP53 mutations and 16q loss. 7 Optimal management of male breast cancer patients would benefit from a better understanding of tumor biology and the mechanisms underlying gender-specific differences.
The 21-gene recurrence score (RS) assay (Oncotype Dx TM , Genomic Health, Redwood City, CA) is included as a prognostic stage tool in the 8th edition of the Cancer Staging Manual by the American Joint Committee of Cancer (AJCC). 8 Many studies in female breast cancer patients have reported an association between the RS risk categories and the likelihood of distant recurrence as well as the magnitude of chemotherapy benefits. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The RS assay results have been reported to significantly change chemotherapy recommendations in as many as [ 30% of women. 11, 18 However, data on the utility of the RS assay in male breast cancer are very limited.
This study assessed the distribution of the RS and to evaluate the benefit of using the RS assay in the management of ER-positive, HER2-negative male breast cancer patients at our institution.
MATERIALS AND METHODS
In this retrospective study, we analyzed a cohort of unselected, consecutive male patients with ER-positive, HER2-negative, lymph node-negative, and few node-positive invasive breast carcinomas diagnosed and treated at our institution with available 21-gene RS assay results. The RS assay is a reverse transcriptase polymerase chain reaction (RT-PCR) based test that utilizes a recurrence score algorithm to calculate the risk of distant recurrence at 10 years in early-stage, ER-positive, HER2-negative breast cancer. The algorithm integrates the expression of 16 cancer-related genes and 5 reference genes to calculate the RS, 9 which stratifies tumors into 3 risk categories: low risk (RS B 17), intermediate risk , and high risk (C 31).
We collected data on clinicopathologic features, treatment and outcome information of our study cohort through a query of our institutional database from a period of February 2006 to August 2016. The clinicopathologic features included age at the time of diagnosis, BRCA mutation status, past oncologic history, tumor type and size, lymphovascular invasion (LVI), expression level of ER and PR by immunohistochemistry (IHC), RS, type of local and systemic treatment, follow-up time, and distant and locoregional recurrence.
Clinicopathologic characteristics of the cohort were summarized using descriptive statistics. Analysis of categorical variables was performed using Fisher's exact test. However, due to the small number of events, most analyses were descriptive and exploratory. The Institutional Review Board approved this study.
RESULTS

Clinicopathologic Features
We identified a total of 38 male patients with ER-positive, HER2-negative carcinoma ( Table 1 ). The median age at diagnosis was 70 (range 40-84) years. The median tumor size was 1.6 (range 0.5-5) cm. Most carcinomas (63.2%; 24/38) were IDC NOS, followed by ductal carcinoma with papillary or solid-papillary features (18.4%; 7/38), micropapillary features (15.8%; 6/38), and apocrine morphology (2.6%; 1/38). The majority of tumors were grade 2 (55.3%; 21/38). Only 7/38 (18.4%) tumors had metastasized to lymph nodes, and 26.3% (10/38) had LVI. All tumors were ER-positive, and 34 of 38 (89.5%) also were PR-positive. The median percentage of ER-positive cells was 95 (range 70-100), and the median percentage of PRpositive cells was 90 (range 0-100).
Twenty-four patients were tested for BRCA1 and BRCA2 germline mutations, and deleterious mutations were identified in four patients (16.7%; 2 BRCA1 and 2 BRCA2). Sixteen (42%) patients had a history of before or subsequent malignancy, the most common of which was prostate cancer (50%; 8/16).
Recurrence Score Assay Results and Clinical Outcome
Of the 38 tumors, 26 (68.4%) had low recurrence score (RS), 9 (23.7%) had intermediate RS, whereas 3 (7.9%) had high RS. The median patient age was 70 years (range 47-84) in the low RS group, 67 years (range 40-81) in the intermediate RS group, and 74 years (range 74-81) in the high RS group. The median tumor size was 1.6 cm (range 0.5-2.7), 2.1 cm (range 0.5-5), and 1.7 cm (range 1.1-3), in the low, intermediate, and high RS groups, respectively. Of the seven lymph node-positive carcinomas, four had intermediate RS and three had low RS. There was no association between the RS risk categories and any of the clinicopathologic variables (p [ 0.05). Both BRCA2 mutation carriers had an intermediate RS. One BRCA1 mutation carrier had a low RS, whereas the other carrier had an intermediate RS.
All patients were treated with total mastectomy and one received postmastectomy radiation therapy. Most patients (34/38; 89.5% were treated with endocrine therapy, primarily tamoxifen (81.6%; 31/38). Only three patients (7.9%) received aromatase inhibitors. Five patients (13.2%) were treated with adjuvant chemotherapy in addition to endocrine therapy, including three of nine in the intermediate RS group and two of three in the high RS group. One 74-year-old patient with a high RS declined chemotherapy due to comorbidity. None of the patients with low RS were treated with chemotherapy.
Median follow-up was 34 months (range 1-133). One patient had a long follow-up of 133 months. He was diagnosed with breast cancer at age of 66 years in 2006, pT1cN0, ER-and PR-positive (90%), HER2-negative. The RS assay was used to guide adjuvant chemotherapy decision, and the result was low risk (RS = 4). He was treated with an aromatase inhibitor and remained free of any recurrence.
None of the 38 patients developed locoregional recurrence. Only one patient (2.6%) developed distant metastasis. This was a 63-year-old man with node-positive IDC and intermediate RS who received adjuvant endocrine therapy combined with chemotherapy. He developed One patient was treated with tamoxifen for 9 months and discontinued due to side effects distant recurrence at 29 months. At the time of the study, this patient was alive with disease. All other patients (97.4%; 37/38) had no evidence of disease at the last follow-up. One patient with low RS died of unknown cause within 2 years of the initial diagnosis.
DISCUSSION
Male and female breast cancers have been suggested to be biologically different. 23 Gene expression profiling revealed a different transcriptomic landscape in female and male breast cancers underpinned by genes involved in energy metabolism, regulation of translation, matrix remodeling, and immune response. 24 Another study of 220 male breast cancers identified 2 clinically significant subtypes different from the 4 intrinsic subtypes of female breast cancer, including prognostically unfavorable luminal M1 tumors with low expression of genes involved in ER signaling, and prognostically favorable luminal M2 tumors with higher expression of ER-associated and immune response genes. 25 Due to the low incidence of male breast cancer and the subsequent lack of randomized clinical trials, systemic treatment of male breast cancer has primarily been extrapolated from female breast cancer patients. Male breast cancer patients have been shown to benefit from endocrine therapy with tamoxifen in a cohort of 257 patients and adjuvant chemotherapy in a smaller study of 135 patients. 26, 27 However, in a large comparative series of [3500 age-and stage-matched male and female patients, only 27% of male breast cancer patients received adjuvant chemotherapy compared with 41% of female breast cancer patients. 28 In addition to successfully using the RS risk categories for adjuvant treatment selection in early-stage, ER-positive, HER2-negative female breast cancer patients, the RS assay is increasingly being incorporated in decision making for node-positive patients. 11, 18, [29] [30] [31] [32] Given the lower incidence of chemotherapy despite the advanced clinical presentation of male breast cancer, the RS assay may allow a better selection of adjuvant systemic therapy in male patients.
Our study describes the association between RS and type of treatment in a cohort of 38 male breast cancer patients. None of the 26 male breast cancer patients with low RS received adjuvant chemotherapy, and none developed locoregional or distant metastasis after a relatively brief median follow-up. In a study of 65 male breast cancer patients from Israel 44.6, 41.5 and 13.9% had low, intermediate, and high risk scores, respectively, in contrast to 68.4, 23.7, and 7.9% in our study. 33 Our patient cohort included fewer node-positive patients (18.4 vs. 35 .4%), suggesting a more stringent use of the original indications (early-stage breast cancer) for requesting the RS assay at our institution.
Additionally, our study confirms that the RS distribution in male breast cancer is similar to that recently reported in a cohort of 2326 female breast cancer patients from our center. 34 Namely, the distribution of RS was 60, 33.4, and 6.6% in female breast cancer versus 68.4, 23.7, and 7.9% in male breast cancer in low, intermediate, and high RS groups, respectively. 34 The rate of distant and locoregional recurrence was very low in female breast cancer patients: in the three RS risk groups, the cumulative incidence at 48 months was 0.41, 1.77, and 3.6% for distant recurrence (Gray's test p \ 0.01) and 0.84, 2.7, and 2.8% for locoregional recurrence (Gray's test p \ 0.01). 34 Although our current cohort of 38 male breast cancer patients is significantly smaller, no locoregional recurrence was observed. Only one patient with intermediate RS developed distant recurrence.
Our patient characteristics were comparable to male breast cancer patients in the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. According to this database between 2003 and 2012, median age of male breast cancer patients was 65 years (range 23-97). Most tumors were IDC NOS (85%) and were positive for ER (95.1%) and PR (86%). Most patients (87.2%) were treated with total mastectomy, and 23.7% received adjuvant radiotherapy. 35 The median age of our patients was 70 years (range 40-84) and 63.2% showed pure IDC histology, whereas the remaining 36.8% were ductal with apocrine, micropapillary, or papillary/solid-papillary features. All tumors in our cohort were ER-positive, and 89.5% also expressed PR. All our patients were treated with total mastectomy, and only one patient received adjuvant radiotherapy. The high rate of total mastectomy most likely explains the low rate of radiotherapy in our cohort, because total mastectomy and breastconserving surgery with radiotherapy are both equally acceptable options for surgical management. 36 Male breast cancer patients have been reported to have up to 41.7% incidence of BRCA2 germline mutations. 37, 38 It has been suggested that germline BRCA-associated, ERpositive breast cancer may be associated with less favorable biology in females. Studies have found an increased rate of high and intermediate RS among BRCA1 and BRCA2 female carriers with ER-positive breast cancer compared with the general population. 39, 40 These patients also were more likely to receive adjuvant therapy versus controls (p = 0.002). 41 Of the 24 patients tested for BRCA1 and BRCA2 germline mutations in our cohort, 16.7% were BRCA mutation carriers. However, the small number of patients with BRCA mutations precludes a comprehensive analysis of the association between BRCA mutation status and the RS data.
Strengths of our study include a population of male breast cancer patients with detailed clinicopathologic variables and clinical outcome data. The main limitations include the retrospective study design, small sample size, limited follow-up (median, 34 months), and low number of events precluding formal statistical analysis of survival functions. Despite the reported genetic differences between female and male breast cancers, and the development and validation of the RS assay in female breast cancer patients, currently there is no evidence to believe that significant gender-specific clinical differences exist that would significantly limit the utility of the RS assay in male breast cancer. 33 In conclusion, the RS distribution in male breast cancer patients appeared similar to that in female breast cancer patients treated at our institution. With limited follow-up, patients with low risk RS were spared chemotherapy and did not develop recurrence. Our results suggest that the RS may have a clinical utility in male breast cancer patients.
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